Design of phase I combination trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Channing J. Paller, Penelope A. Bradbury, S. Percy Ivy, Lesley Seymour, Patricia M. LoRusso, Laurence Baker, Larry Rubinstein, Erich Huang, Deborah Collyar, Susan Groshen, Steven Reeves, Lee M. Ellis, Daniel J. Sargent, Gary L. Rosner, Michael L. LeBlanc, Mark J. Ratain

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Anticancer drugs are combined in an effort to treat a heterogeneous tumor or to maximize the pharmacodynamic effect. The development of combination regimens, while desirable, poses unique challenges. These include the selection of agents for combination therapy that may lead to improved efficacy while maintaining acceptable toxicity, the design of clinical trials that provide informative results for individual agents and combinations, and logistic and regulatory challenges. The phase I trial is often the initial step in the clinical evaluation of a combination regimen. In view of the importance of combination regimens and the challenges associated with developing them, the Clinical Trial Design (CTD) Task Force of the National Cancer Institute Investigational Drug Steering Committee developed a set of recommendations for the phase I development of a combination regimen. The first two recommendations focus on the scientific rationale and development plans for the combination regimen; subsequent recommendations encompass clinical design aspects. The CTD Task Force recommends that selection of the proposed regimens be based on a biologic or pharmacologic rationale supported by clinical and/or robust and validated preclinical evidence, and accompanied by a plan for subsequent development of the combination. The design of the phase I clinical trial should take into consideration the potential pharmacokinetic and pharmacodynamic interactions as well as overlapping toxicity. Depending on the specific hypothesized interaction, the primary endpoint may be dose optimization, pharmacokinetics, and/or pharmacodynamics (i.e., biomarker).

Original languageEnglish (US)
Pages (from-to)4210-4217
Number of pages8
JournalClinical Cancer Research
Volume20
Issue number16
DOIs
StatePublished - Aug 15 2014

Fingerprint

Pharmacy and Therapeutics Committee
Investigational Drugs
Advisory Committees
Clinical Trials
Pharmacokinetics
Clinical Trials, Phase I
National Cancer Institute (U.S.)
Biomarkers
Pharmaceutical Preparations
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Design of phase I combination trials : Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. / Paller, Channing J.; Bradbury, Penelope A.; Ivy, S. Percy; Seymour, Lesley; LoRusso, Patricia M.; Baker, Laurence; Rubinstein, Larry; Huang, Erich; Collyar, Deborah; Groshen, Susan; Reeves, Steven; Ellis, Lee M.; Sargent, Daniel J.; Rosner, Gary L.; LeBlanc, Michael L.; Ratain, Mark J.

In: Clinical Cancer Research, Vol. 20, No. 16, 15.08.2014, p. 4210-4217.

Research output: Contribution to journalArticle

Paller, CJ, Bradbury, PA, Ivy, SP, Seymour, L, LoRusso, PM, Baker, L, Rubinstein, L, Huang, E, Collyar, D, Groshen, S, Reeves, S, Ellis, LM, Sargent, DJ, Rosner, GL, LeBlanc, ML & Ratain, MJ 2014, 'Design of phase I combination trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee', Clinical Cancer Research, vol. 20, no. 16, pp. 4210-4217. https://doi.org/10.1158/1078-0432.CCR-14-0521
Paller, Channing J. ; Bradbury, Penelope A. ; Ivy, S. Percy ; Seymour, Lesley ; LoRusso, Patricia M. ; Baker, Laurence ; Rubinstein, Larry ; Huang, Erich ; Collyar, Deborah ; Groshen, Susan ; Reeves, Steven ; Ellis, Lee M. ; Sargent, Daniel J. ; Rosner, Gary L. ; LeBlanc, Michael L. ; Ratain, Mark J. / Design of phase I combination trials : Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 16. pp. 4210-4217.
@article{878b335459914929b8ee62636aeee06d,
title = "Design of phase I combination trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee",
abstract = "Anticancer drugs are combined in an effort to treat a heterogeneous tumor or to maximize the pharmacodynamic effect. The development of combination regimens, while desirable, poses unique challenges. These include the selection of agents for combination therapy that may lead to improved efficacy while maintaining acceptable toxicity, the design of clinical trials that provide informative results for individual agents and combinations, and logistic and regulatory challenges. The phase I trial is often the initial step in the clinical evaluation of a combination regimen. In view of the importance of combination regimens and the challenges associated with developing them, the Clinical Trial Design (CTD) Task Force of the National Cancer Institute Investigational Drug Steering Committee developed a set of recommendations for the phase I development of a combination regimen. The first two recommendations focus on the scientific rationale and development plans for the combination regimen; subsequent recommendations encompass clinical design aspects. The CTD Task Force recommends that selection of the proposed regimens be based on a biologic or pharmacologic rationale supported by clinical and/or robust and validated preclinical evidence, and accompanied by a plan for subsequent development of the combination. The design of the phase I clinical trial should take into consideration the potential pharmacokinetic and pharmacodynamic interactions as well as overlapping toxicity. Depending on the specific hypothesized interaction, the primary endpoint may be dose optimization, pharmacokinetics, and/or pharmacodynamics (i.e., biomarker).",
author = "Paller, {Channing J.} and Bradbury, {Penelope A.} and Ivy, {S. Percy} and Lesley Seymour and LoRusso, {Patricia M.} and Laurence Baker and Larry Rubinstein and Erich Huang and Deborah Collyar and Susan Groshen and Steven Reeves and Ellis, {Lee M.} and Sargent, {Daniel J.} and Rosner, {Gary L.} and LeBlanc, {Michael L.} and Ratain, {Mark J.}",
year = "2014",
month = "8",
day = "15",
doi = "10.1158/1078-0432.CCR-14-0521",
language = "English (US)",
volume = "20",
pages = "4210--4217",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Design of phase I combination trials

T2 - Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

AU - Paller, Channing J.

AU - Bradbury, Penelope A.

AU - Ivy, S. Percy

AU - Seymour, Lesley

AU - LoRusso, Patricia M.

AU - Baker, Laurence

AU - Rubinstein, Larry

AU - Huang, Erich

AU - Collyar, Deborah

AU - Groshen, Susan

AU - Reeves, Steven

AU - Ellis, Lee M.

AU - Sargent, Daniel J.

AU - Rosner, Gary L.

AU - LeBlanc, Michael L.

AU - Ratain, Mark J.

PY - 2014/8/15

Y1 - 2014/8/15

N2 - Anticancer drugs are combined in an effort to treat a heterogeneous tumor or to maximize the pharmacodynamic effect. The development of combination regimens, while desirable, poses unique challenges. These include the selection of agents for combination therapy that may lead to improved efficacy while maintaining acceptable toxicity, the design of clinical trials that provide informative results for individual agents and combinations, and logistic and regulatory challenges. The phase I trial is often the initial step in the clinical evaluation of a combination regimen. In view of the importance of combination regimens and the challenges associated with developing them, the Clinical Trial Design (CTD) Task Force of the National Cancer Institute Investigational Drug Steering Committee developed a set of recommendations for the phase I development of a combination regimen. The first two recommendations focus on the scientific rationale and development plans for the combination regimen; subsequent recommendations encompass clinical design aspects. The CTD Task Force recommends that selection of the proposed regimens be based on a biologic or pharmacologic rationale supported by clinical and/or robust and validated preclinical evidence, and accompanied by a plan for subsequent development of the combination. The design of the phase I clinical trial should take into consideration the potential pharmacokinetic and pharmacodynamic interactions as well as overlapping toxicity. Depending on the specific hypothesized interaction, the primary endpoint may be dose optimization, pharmacokinetics, and/or pharmacodynamics (i.e., biomarker).

AB - Anticancer drugs are combined in an effort to treat a heterogeneous tumor or to maximize the pharmacodynamic effect. The development of combination regimens, while desirable, poses unique challenges. These include the selection of agents for combination therapy that may lead to improved efficacy while maintaining acceptable toxicity, the design of clinical trials that provide informative results for individual agents and combinations, and logistic and regulatory challenges. The phase I trial is often the initial step in the clinical evaluation of a combination regimen. In view of the importance of combination regimens and the challenges associated with developing them, the Clinical Trial Design (CTD) Task Force of the National Cancer Institute Investigational Drug Steering Committee developed a set of recommendations for the phase I development of a combination regimen. The first two recommendations focus on the scientific rationale and development plans for the combination regimen; subsequent recommendations encompass clinical design aspects. The CTD Task Force recommends that selection of the proposed regimens be based on a biologic or pharmacologic rationale supported by clinical and/or robust and validated preclinical evidence, and accompanied by a plan for subsequent development of the combination. The design of the phase I clinical trial should take into consideration the potential pharmacokinetic and pharmacodynamic interactions as well as overlapping toxicity. Depending on the specific hypothesized interaction, the primary endpoint may be dose optimization, pharmacokinetics, and/or pharmacodynamics (i.e., biomarker).

UR - http://www.scopus.com/inward/record.url?scp=84905983305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905983305&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-0521

DO - 10.1158/1078-0432.CCR-14-0521

M3 - Article

C2 - 25125258

AN - SCOPUS:84905983305

VL - 20

SP - 4210

EP - 4217

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -